Teva Eyes Low-Single-Digit Global Generics Growth After 15% U.S. Biosimilars Surge
Teva’s U.S. generics and biosimilars unit posted 15% growth in 2024 and 2% in 2025, while global generics revenue held flat year-over-year. Consensus EPS for 2026 remains unchanged at $2.72 as Teva targets low-single-digit growth in its global generics business through complex and biosimilar launches.
1. Teva's Recent Sales Performance
In 2024, Teva’s U.S. generics and biosimilars business grew by 15%, driven largely by new biosimilar product launches. In 2025, U.S. sales rose just 2% as strong biosimilar gains were offset by lower revenues from generic Revlimid and Victoza.
2. Forecast for Global Generics Growth
Teva’s global generics revenue was flat in 2025 compared with the prior year. The company forecasts low-single-digit growth in its global generics business for 2026, fueled by planned launches of complex generics in the U.S. and multiple product rollouts in ex-U.S. markets.
3. EPS Stability and Stock Performance
The consensus 2026 EPS estimate remains steady at $2.72, reflecting unchanged profitability expectations. Teva’s shares have surged 103% over the past year as investors back its shift toward higher-margin complex generics and biosimilars.